Incidence of Pneumocystis jiroveci pneumonia in patients with ANCA-associated vasculitis initiating therapy with rituximab or cyclophosphamide.
Elizabeth NettletonSebastian Eduardo SattuiZachary WallaceMichael PutmanPublished in: Arthritis care & research (2023)
Rates of PJP in AAV patients were lower than previously observed and few cases occurred during rituximab maintenance therapy. PJP prophylaxis was associated with adverse events.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- risk factors
- peritoneal dialysis
- stem cells
- low dose
- prognostic factors
- chronic lymphocytic leukemia
- hodgkin lymphoma
- patient reported outcomes
- gene therapy
- patient reported
- extracorporeal membrane oxygenation
- replacement therapy